Table 2 Combination regimens with venetoclax under investigation in AML.

From: New directions for emerging therapies in acute myeloid leukemia: the next chapter

Doublet Venetoclax backbone

Triplet Venetoclax + HMA backbone

HMA (eg, AZA, DEC)

FLT3 inhibitor (eg, midostaurin, gilteritinib, quizartinib)

LDAC

IDH1/2 inhibitor (eg, ivosidenib, enasidenib)

FLT3 inhibitor (eg, midostaurin, gilteritinib, quizartinib)

APR-246 (TP53 target)

IDH1/2 inhibitor (eg, ivosidenib, enasidenib)

MCL1 inhibitor (CYC065, AMG 176)

MDM2 antagonist (eg, idasanutlin)

Immune therapies (CD123 ADC, CD70 antibody, PD-1 inhibitors, TIM-3 inhibitors, CD47 antibodies)

CDK9 inhibitora (eg, alvocidib, voruciclib)

 

MCL1 inhibitor (S64315, AZD5991)

 
  1. ADC antibody-drug conjugate, AML acute myeloid leukemia, AZA azacitidine, CDK cyclin-dependent kinase, DEC decitabine, FLT3 FMS-like tyrosine kinase 3, HMA hypomethylating agent, IDH isocitrate dehydrogenase, LDAC low-dose cytarabine, MCL1 myeloid cell leukemia-1, MDM2 mouse double minute 2, PD-1 programmed cell death protein 1, TIM-3 T cell immunoglobulin and mucin domain-containing protein 3.
  2. aData from Bogenberger et al.24 and Luedtke et al.25.
Back to article page